本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事离任情况 (一) 提前离任的基本情况 北京天智航医疗科技股份有限公司（以下简称"公司"）董事会于 2025 年 9 月 25 日收到肖治先生的辞职报告，肖治先生因工作调整辞去公司董事、董事会 战略委员会委员职务，自 2025 年 9 月 25 日起生效。 | 姓名 | 离任 | 离任时间 | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 职务 | | | 到期日 | | | | | | | | | | | | | 股子公司任职 | 公开承诺 | | 肖治 | 董事 | 2025 年 9 | | 2026 9 | 年 | 工作调整 | 否 | 否 | | | | 月 25 | 日 | 月 7 | 日 | | | | 证券代码：688277 证券简称：天智航 公告编号：2025-039 北京天智航医疗科技股份 ...

证券代码：688277 证券简称：天智航 公告编号：2025-040 北京天智航医疗科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 10 月 16 日 10 点 00 分 召开地点：北京市海淀区建枫路（南延）中关村西三旗金隅科技园 8 号院 2 号楼北京天智航医疗科技股份有限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 16 日 至2025 年 10 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25， ...

Core Insights - The article discusses the advancements and market potential of spinal surgery robots, highlighting their role in enhancing surgical precision and safety through integrated technologies [1][16]. Market Overview - The global spinal surgery robot market is projected to reach $900 million by 2031, with a compound annual growth rate (CAGR) of 19.6% in the coming years [1]. - The leading manufacturers in the spinal surgery robot market include Medtronic, Globus Medical, Zimmer Biomet, Tianzhihang, and Brainlab, with the top four companies holding approximately 94.0% of the market share in 2024 [5]. Product Segmentation - Guided surgical robots dominate the market, accounting for about 99.0% of the total market share [8]. - Minimally invasive surgery is the largest application segment, representing approximately 80.7% of the demand [10]. Market Drivers - Key drivers for the spinal surgery robot market include technological innovation, increasing clinical demand, and the ongoing digital transformation in the healthcare sector [16]. - The aging global population and the rise in spinal degenerative diseases are contributing to the growing need for precise and minimally invasive surgical solutions [16]. Challenges - The market faces challenges such as high equipment procurement and maintenance costs, which create economic pressure on smaller hospitals [17]. - There is a need for extensive training and integration with existing imaging and navigation systems, which can hinder adoption in underdeveloped regions [17]. Future Trends - The spinal surgery robot industry is expected to accelerate towards greater intelligence, integration, and minimally invasive techniques [18]. - Future robots will likely incorporate advanced technologies such as AI, big data, and machine vision for improved decision-making and surgical planning [18].

Group 1 - The A-share technology stocks continue to strengthen, with the Sci-Tech Innovation Index rising nearly 1% on September 25, 2023 [1] - The Tianhong Sci-Tech Innovation Index ETF (589860) increased by 0.90%, with a trading volume exceeding 28 million yuan, indicating active trading [1] - In the robotics sector, the Robotics ETF (159770) rose by 0.44%, with a trading volume exceeding 200 million yuan and a turnover rate of over 2.5% [1] Group 2 - The Robotics ETF (159770) received a net subscription of 12 million units, reflecting strong investor interest [2] - The Tianhong Sci-Tech Innovation Index ETF closely tracks the Sci-Tech Innovation Index, which covers approximately 97% of the market capitalization of the Sci-Tech Innovation Board, focusing on small-cap hard technology companies [2] - The Robotics ETF tracks the CSI Robotics Index, which includes companies involved in system solutions, digital workshops, automation equipment manufacturing, and other robotics-related sectors [2] Group 3 - Alibaba Cloud and NVIDIA have reached a collaboration in the Physical AI field, integrating NVIDIA's software stack into Alibaba's AI platform to enhance development cycles for applications like embodied intelligence and assisted driving [3] - Qualcomm's China Chairman indicated that the future scale of robotics and wearable devices could equal or exceed that of smartphones, highlighting the growth potential in these sectors [3] - Recent developments in the robotics industry, including Tesla's announcement of a compensation plan linked to the delivery of 1 million Optimus humanoid robots, have boosted market sentiment [3] Group 4 - CITIC Securities noted that the humanoid robotics index's performance is significantly influenced by Tesla's advancements in robotics, with a shift from theme investment to production expectations [4] - The upcoming Gen3 hardware release is expected to provide clearer production guidance and present historic opportunities for the sector [4] - The focus on supply chain certainty and new hardware directions is crucial for the industry, along with attention to the progress of domestic applications [4]

Core Viewpoint - Tianzhihang Medical Technology Co., Ltd. has shown significant stock performance and financial growth, particularly in the orthopedic surgical navigation robot sector, despite facing challenges in net profit. Group 1: Stock Performance - On September 16, Tianzhihang's stock rose by 2.10%, reaching 18.00 CNY per share, with a trading volume of 77.72 million CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 8.148 billion CNY [1] - Year-to-date, Tianzhihang's stock price has increased by 80.18%, with a 1.24% rise over the last five trading days, an 8.49% decline over the last 20 days, and a 29.03% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 17, where it recorded a net purchase of 26.27 million CNY [1] Group 2: Company Overview - Tianzhihang, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots [2] - The company's revenue composition includes 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [2] - As of June 30, the number of shareholders decreased by 7.14% to 15,400, with an average of 29,308 circulating shares per person, an increase of 8.48% [2] Group 3: Financial Performance - For the first half of 2025, Tianzhihang reported revenue of 125 million CNY, a year-on-year increase of 114.89%, while the net profit attributable to shareholders was -57.55 million CNY, a decrease of 23.80% year-on-year [2] - As of June 30, 2025, the top ten circulating shareholders included Huaxia CSI Robot ETF, which holds 7.10 million shares as a new shareholder [2]

减持计划的实施结果情况 2025 年 5 月 20 日，公司收到先进制造基金及其一致行动人京津冀基金出 具的《关于北京天智航医疗科技股份有限公司的股份减持计划告知函》，公司于 2025 年 5 月 21 日在上海证券交易所网站（www.sse.com.cn）披露了《股东减持 股份计划公告》（公告编号：2025-025）。截至 2025 年 9 月 11 日，本次减持计划 时间已届满。根据先进制造基金及其一致行动人京津冀基金出具的股份减持完成 告知函，本次减持计划时间区间内，先进制造基金通过集中竞价交易的方式减持 本公司无限售流通股股份 2,255,147 股，占公司总股本的 0.50%；先进制造基金 通过大宗交易的方式减持本公司无限售流通股股份 300,000 股，占公司总股本的 0.07%。京津冀基金通过集中竞价交易的方式减持本公司无限售流通股股份 2,255,303 股，占公司总股本的 0.50%；京津冀基金通过大宗交易的方式减持本公 司无限售流通股股份 300,000 股，占公司总股本的 0.07%。 证券代码：688277 证券简称：天智航 公告编号：2025-038 北京天智航医疗科技股份有限公司 ...

Core Points - The company, Beijing Tinavi Medical Technology Co., Ltd., will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025 [2][3] - The briefing aims to provide investors with a comprehensive understanding of the company's semi-annual operating results and financial status [2][3] - The event will be held online at the Shanghai Stock Exchange Roadshow Center, allowing for interactive Q&A [2][4] Meeting Details - The meeting is scheduled for September 17, 2025, from 15:00 to 17:00 [4][5] - It will take place at the Shanghai Stock Exchange Roadshow Center [4][5] - Participants will include the company's General Manager, Independent Director, Chief Financial Officer, and Board Secretary [3] Investor Participation - Investors can log in to the Shanghai Stock Exchange Roadshow Center to participate in the briefing [4][5] - Questions can be submitted from September 10 to September 16, 2025, through the Roadshow Center or via the company's email [4][5] - The company will address commonly asked questions during the briefing [3][5]

经中国证券监督管理委员会（以下简称"中国证监会"）"证监许可〔2020〕 1001 号文"批准，北京天智航医疗科技股份有限公司（以下简称"公司"或"天 智航"）首次公开发行人民币普通股（A 股）股票 4,190.00 万股。本次公司发行 新股的发行价为 12.04 元/股，募集资金总额为 504,476,000.00 元，扣除发行费用 56,175,293.91 元后，实际募集资金净额为 448,300,706.09 元。本次公开发行股票 于 2020 年 7 月 7 日在上海证券交易所上市。中信建投证券股份有限公司（以下 简称"中信建投证券"或"保荐人"）担任本次公开发行股票的保荐人。 经中国证监会"证监许可〔2022〕797 号文"批准，天智航向特定对象发行 人民币普通股（A 股）股票 29,545,091 股。本次公司发行新股的发行价为 12.53 元/股，募集资金总额为 370,199,990.23 元，扣除发行费用 10,443,396.23 元后， 实际募集资金净额为 359,756,594.00 元。本次公开发行股票于 2023 年 3 月 7 日 在上海证券交易所上市。中信建投证券担任本次向特 ...

证券代码：688277 证券简称：天智航 公告编号：2025-037 北京天智航医疗科技股份有限公司 关于参加 2025 年半年度科创板医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 10 日至 9 月 16 日 16:00 前登录上证路演中心网 站首页点击"提问预征集"栏目或通过公司邮箱 tinavi@tinavi.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 会议召开时间：2025 年 9 月 17 日 15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/）（以下简称"上证路演中心"） 会议召开方式：上证路演中心网络文字互动 北京天智航医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 ...

Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]